Today: 28 June 2026
Browse Category

Biotechnology 4 November 2025 - 17 November 2025

Metsera (MTSR) Delists as Pfizer Closes Up to $10 Billion Obesity Drug Deal – All the Key Updates on November 17, 2025

Metsera (MTSR) Delists as Pfizer Closes Up to $10 Billion Obesity Drug Deal – All the Key Updates on November 17, 2025

Pfizer completed its $10 billion acquisition of Metsera on November 13, 2025, making Metsera a wholly owned subsidiary and delisting its shares from Nasdaq. Metsera stock last traded at about $70.50 per share before removal. S&P and FTSE Russell are dropping MTSR from their indices. Antitrust scholars are citing Novo Nordisk’s failed bid as a case study in attempted monopolization.
17 November 2025
···
Galmed Pharmaceuticals (GLMD) Soars on New Cancer Drug Combo Data: What Today’s Breakthrough Means for Investors – November 17, 2025

Galmed Pharmaceuticals (GLMD) Soars on New Cancer Drug Combo Data: What Today’s Breakthrough Means for Investors – November 17, 2025

Galmed Pharmaceuticals reported that a triple-drug combination of Aramchol, Stivarga, and metformin sharply increased tumor cell killing in GI cancer models. Shares jumped as much as 38.6% premarket and traded around $1.18 by afternoon, with volume exceeding 41 million shares. The company plans a Phase 1b trial at VCU Massey Comprehensive Cancer Center in early 2026. New U.S. patent applications have been filed for the combination.
17 November 2025
···
Autonomix Medical (AMIX) Stock Doubles on New Pancreatic Cancer Quality‑of‑Life Data – November 17, 2025 Update

Autonomix Medical (AMIX) Stock Doubles on New Pancreatic Cancer Quality‑of‑Life Data – November 17, 2025 Update

Autonomix Medical reported 20–30-point gains in quality-of-life scores at three months in a subgroup analysis from its PoC 1 study for severe pancreatic cancer pain. Even Stage 4 patients saw durable symptom and function improvements after nerve ablation. AMIX shares nearly doubled intraday on heavy volume, ranking among Nasdaq’s top gainers. The company remains pre-revenue and highly volatile.
17 November 2025
··
Zymeworks (ZYME) Soars on Positive Phase 3 Ziihera Data in Gastric Cancer – What Today’s Breakthrough Means for the Stock and Patients

Zymeworks (ZYME) Soars on Positive Phase 3 Ziihera Data in Gastric Cancer – What Today’s Breakthrough Means for the Stock and Patients

Zymeworks reported its Phase 3 HERIZON-GEA-01 trial showed Ziihera (zanidatamab-hrii) combinations outperformed trastuzumab plus chemotherapy in HER2-positive gastroesophageal adenocarcinoma. The triple-combination arm also improved overall survival. Jazz Pharmaceuticals plans to file for FDA approval in the first half of 2026. ZYME shares jumped 30–50% pre-market on the news.
17 November 2025
····
Precigen (PGEN) Soars as PAPZIMEOS Launch, Q3 2025 Earnings and Fresh Analyst Upgrades Ignite Investor Interest

Precigen (PGEN) Soars as PAPZIMEOS Launch, Q3 2025 Earnings and Fresh Analyst Upgrades Ignite Investor Interest

Precigen shares surged nearly 30% intraday on November 14, trading around $4.90–$5.00 after reporting Q3 revenue of $2.92 million, far above expectations. The company’s PAPZIMEOS therapy for recurrent respiratory papillomatosis is fully launched in the U.S., with over 100 patients enrolled and broad insurance coverage. Precigen has also filed for European approval of PAPZIMEOS.
14 November 2025
···
Scholar Rock (NASDAQ: SRRK) Soars on FDA Progress, $200M ATM and Q3 2025 Earnings – November 14, 2025 Update

Scholar Rock (NASDAQ: SRRK) Soars on FDA Progress, $200M ATM and Q3 2025 Earnings – November 14, 2025 Update

Scholar Rock shares surged 26% to $37.98 after an FDA meeting on its SMA therapy and the launch of a $200 million at-the-market stock offering. The company reported a Q3 2025 net loss of $102.2 million, up from $64.5 million a year earlier, with no revenue as it prepares for a potential U.S. launch in 2026. Trading volume topped 2.7 million shares.
14 November 2025
····
Clearmind Medicine (CMND) Stock Soars as FDA‑Regulated Alcohol Use Disorder Trial Expands to Hadassah – November 13, 2025

Clearmind Medicine (CMND) Stock Soars as FDA‑Regulated Alcohol Use Disorder Trial Expands to Hadassah – November 13, 2025

Clearmind Medicine shares surged Thursday after the company received final approval to expand its FDA-regulated Phase 1/2a trial for Alcohol Use Disorder to Hadassah Medical Center in Jerusalem. The firm also filed for a registered direct offering of shares and pre-funded warrants, raising new capital but prompting dilution concerns among investors. The trial now includes sites at Yale, Johns Hopkins, Tel Aviv Sourasky, and Hadassah.
13 November 2025
··
Humacyte (HUMA) Q3 2025: Symvess Sales Surge; IND Filed for CABG as Dialysis Data Advance — Nov 12, 2025

Humacyte (HUMA) Q3 2025: Symvess Sales Surge; IND Filed for CABG as Dialysis Data Advance — Nov 12, 2025

Humacyte reported Q3 revenue of $753,000, with $703,000 from Symvess sales, and a net loss of $17.5 million (GAAP EPS −$0.11). The company said 25 Value Analysis Committee approvals now cover 92 U.S. hospitals, with 16 hospitals ordering Symvess. Positive two-year Phase 3 dialysis trial results were presented, and an IND was submitted for a coronary bypass graft study in 2026.
12 November 2025
··
Quoin Pharmaceuticals (QNRX) Soars After Hitting 4%/5% Topical Rapamycin Targets; Clinical Batches This Quarter, Human Trials 1H 2026 [Nov. 11, 2025]

Quoin Pharmaceuticals (QNRX) Soars After Hitting 4%/5% Topical Rapamycin Targets; Clinical Batches This Quarter, Human Trials 1H 2026 [Nov. 11, 2025]

Quoin Pharmaceuticals announced it achieved 4% rapamycin in a topical lotion and 5% in a dermal patch, clearing a key formulation barrier for human trials. QNRX shares surged, with pre-market gains near 66%. Clinical and stability batch manufacturing is set for late 2025, with first-in-human studies planned for early 2026 targeting microcystic lymphatic and venous malformations.
11 November 2025
···
enGene (ENGN) soars after detailing 62% 6‑month complete response in pivotal bladder‑cancer trial; BLA still targeted for 2H 2026

enGene (ENGN) soars after detailing 62% 6‑month complete response in pivotal bladder‑cancer trial; BLA still targeted for 2H 2026

enGene Holdings reported a 62% complete response rate at 6 months in its pivotal Phase 2 LEGEND trial of detalimogene voraplasmid for high-risk, BCG-unresponsive NMIBC with CIS. The company enrolled 125 patients, above target. Shares surged as much as 62% pre-market after the update. Safety data showed 42% of patients had treatment-related adverse events, mostly mild.
11 November 2025
···
Viking Therapeutics (VKTX) Today — Nov 9, 2025: New Institutional Buying, Fresh Technical Levels, and Key Catalysts Ahead

Viking Therapeutics (VKTX) Today — Nov 9, 2025: New Institutional Buying, Fresh Technical Levels, and Key Catalysts Ahead

Ethos Financial Group disclosed a new stake in Viking Therapeutics, acquiring 10,548 VKTX shares valued at about $280,000. VKTX closed Friday at $36.77 on volume of 4.65 million. Recent insider sales totaled 111,359 shares, while institutional ownership stands near 76%. Clinical updates include positive VK2735 obesity data and ongoing Phase 3 enrollment.
9 November 2025
·
Tenaya Therapeutics (TNYA) on Nov. 8, 2025: FDA Places Clinical Hold on TN‑201 Trial as AHA 2025 Showcases Encouraging MyPEAK‑1 Data

Tenaya Therapeutics (TNYA) on Nov. 8, 2025: FDA Places Clinical Hold on TN‑201 Trial as AHA 2025 Showcases Encouraging MyPEAK‑1 Data

The FDA placed a clinical hold on Tenaya’s MyPEAK-1 trial for TN-201, requiring protocol changes for patient monitoring and immunosuppression. Tenaya reported new interim data showing six treated patients had increased MyBP-C protein and improved cardiac biomarkers, with all six no longer symptomatic. Shares dropped over 20% after the hold was announced. The company does not expect data timelines to change.
8 November 2025
·
Intellia Therapeutics (NTLA) plunges after patient death in pivotal CRISPR trial; Q3 update, analyst downgrades and what to watch next [Nov. 7, 2025]

Intellia Therapeutics (NTLA) plunges after patient death in pivotal CRISPR trial; Q3 update, analyst downgrades and what to watch next [Nov. 7, 2025]

Intellia said a patient in its Phase 3 MAGNITUDE trial died after severe liver toxicity; FDA clinical holds on MAGNITUDE and MAGNITUDE-2 remain. NTLA shares fell as RBC cut its price target to $9, citing increased risk. The company reported $669.9 million in cash and securities, expecting its runway to last into mid-2027. Work continues on its hereditary angioedema program.
7 November 2025
···
Iovance Biotherapeutics (IOVA) Q3 2025: Revenue Climbs ~13% to ~$68M; Gross Margin Hits 43%, Guidance Reaffirmed — November 6, 2025

Iovance Biotherapeutics (IOVA) Q3 2025: Revenue Climbs ~13% to ~$68M; Gross Margin Hits 43%, Guidance Reaffirmed — November 6, 2025

Iovance Biotherapeutics reported Q3 2025 revenue of $67.5 million, up 13% sequentially but below analyst expectations, and a net loss of $91.3 million, or $0.25 per share. Gross margin rose to 43%. Management reaffirmed full-year revenue guidance of $250–$300 million. Over 80 U.S. treatment centers are now active, and cash reserves totaled $307 million at quarter’s end.
6 November 2025
···
Novavax (NVAX) Raises 2025 Revenue Outlook After Q3 Beat; Sanofi Milestones Drive Guidance — November 6, 2025

Novavax (NVAX) Raises 2025 Revenue Outlook After Q3 Beat; Sanofi Milestones Drive Guidance — November 6, 2025

Novavax raised its FY2025 adjusted revenue outlook to $1.04–$1.06 billion after reporting Q3 revenue of $70 million, above estimates. The company posted a GAAP net loss of $202 million for the quarter, impacted by $126 million in non-cash charges tied to Maryland site consolidation and debt. Two $25 million milestone payments from Sanofi will be recognized in Q4. Cash stood at $778 million as of September 30.
6 November 2025
·····
From Crash to Breakthrough: Why Lunai Bioworks (LNAI) Is Suddenly on Investors’ Radar

From Crash to Breakthrough: Why Lunai Bioworks (LNAI) Is Suddenly on Investors’ Radar

Lunai Bioworks (NASDAQ: LNAI) shares surged over 15% to around $1 after announcing preclinical success in pancreatic cancer immunotherapy on Nov. 5, 2025. The stock remains down more than 85% year-over-year and trades near all-time lows after a 10:1 reverse split in September. Lunai is pre-revenue, posted a $178 million net loss over the past year, and faces severe liquidity issues.
5 November 2025
···
Recursion Pharmaceuticals (RXRX) – AI Drug Discovery Breakthroughs, CEO Shakeup & 2025 Stock Outlook

Recursion Pharmaceuticals (RXRX) – AI Drug Discovery Breakthroughs, CEO Shakeup & 2025 Stock Outlook

Recursion Pharmaceuticals shares fell 15% in the past week to around $5, down 55% from their 52-week high. Q3 2025 revenue missed estimates at $5 million, with net loss widening to $162.3 million. The company announced a $30 million milestone payment from Roche/Genentech and a CEO transition, with Najat Khan set to take over in January. Recursion holds about $785 million in cash, enough to fund operations through 2027.
5 November 2025
··
‘Yeast Survives Mars’ & ESA’s ‘Protein Out of Thin Air’: How Biology Is Rewriting the Mars Menu — and What It Means for Investors

‘Yeast Survives Mars’ & ESA’s ‘Protein Out of Thin Air’: How Biology Is Rewriting the Mars Menu — and What It Means for Investors

ESA has launched the HOBI‑WAN pilot to test microbial protein production from hydrogen, oxygen, and CO₂ in microgravity, with OHB System AG and Solar Foods as partners. An eight-month ground phase begins now, ahead of an ISS flight model. Indian researchers report yeast surviving Mars-like shock waves and toxic salts. Solar Foods shares traded near €5.5 in Helsinki, OHB SE closed at €106 in Frankfurt.
5 November 2025
····
COMPASS Pathways (CMPS) Psychedelic Breakthrough Stock – Latest News, Analysis & 2025 Outlook

COMPASS Pathways (CMPS) Psychedelic Breakthrough Stock – Latest News, Analysis & 2025 Outlook

COMPASS Pathways’ stock traded near $6 on Nov. 4, 2025, flat after a recent pullback and well above mid-year lows. The company reported a net loss of $137.7 million in Q3, with $185.9 million in cash on hand. Its lead psilocybin therapy met the primary endpoint in a Phase 3 trial for treatment-resistant depression in June. COMPASS is accelerating commercial plans and expects key data readouts in 2026.
4 November 2025
·
1 … 12 13 14 15 16 … 19

Stock Market Today

  • Foreign Funds Dominate Ownership of Spain's Ibex 35 Stock Market
    June 28, 2026, 6:45 AM EDT. The Spanish stock market is increasingly controlled by foreign investors, with nearly 49% of shares owned by nonresidents as of 2024, rising to over 60% by market capitalization. Key players include investment giants BlackRock, Vanguard, and Norway's sovereign wealth fund. The trend reflects a reduction in household ownership from 35% in 1998 to under 16% today, aligning Spain with other EU markets like the UK and France. Experts note that international ownership brings enhanced corporate governance and market liquidity, though it also presents new challenges. The Ibex 35's revenue is also globally diversified, with 65% generated abroad. This shift highlights the global nature of Spain's equities and the growing role of international capital in its market.

Latest articles

Wall Street Feels the Heat (and Thrill): Fed Cuts, Tariffs & Mega-Mergers Set NYSE Buzz

US Stock Market Today: Live Updates 28.06.2026

28 June 2026
LIVEMarkets rolling coverageStarted: June 28, 2026, 4:00 AM EDTUpdated: June 28, 2026, 6:55 AM EDT Foreign Funds Dominate Ownership of Spain's Ibex 35 Stock Market June 28, 2026, 6:45 AM EDT. The Spanish stock market is increasingly controlled by foreign investors, with nearly 49% of shares owned by nonresidents as of 2024, rising to over 60% by market capitalization. Key players include investment giants BlackRock, Vanguard, and Norway’s sovereign wealth fund. The trend reflects a reduction in household ownership from 35% in 1998 to under 16% today, aligning Spain with other EU markets like the UK and France. Experts note
Go toTop